Robert Rönn, SVP and Head of R&D: “My vision is to develop several new drugs based on amorphOX™”
In recent years, Orexo has invested in its development pipeline with a focus on OX124, a life-saving overdose medication. In parallel, the company has developed a new drug delivery platform, amorphOX™, that will serve as the backbone in other future pharmaceuticals. In an interview with Robert Rönn, SVP and Head of Research and Development at Orexo, he reflects on creating pioneering pharmaceuticals, filing successful patents and his vision for the new drug delivery platform. [P:\Internal Information\Robert Robert Rönn, SVP and Head of R&D atRönn\JELA_OREX_210906 Orexo